Drug Type Fab fragment, Biosimilar |
Synonyms Ranibizumab Biosimilar (Actor Pharmaceuticals Pty Ltd), RANIVIZ |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Choroidal Neovascularization | AU | 20 Dec 2023 | |
Diabetic macular oedema | AU | 20 Dec 2023 | |
Proliferative retinopathy with diabetes mellitus | AU | 20 Dec 2023 | |
Retinal vein occlusion-related macular edema | AU | 20 Dec 2023 | |
Wet age-related macular degeneration | AU | 20 Dec 2023 |